Purpose Of Review: Endometrial cancer is a highly treatable cancer; however, 13 to 15% of cases recur. Traditional cytotoxic chemotherapies have produced modest results, but new treatments show promise. This information was compiled from an extensive literature search, which was completed in order to summarize current data in this review. Our objective was to describe new therapies for recurrent endometrial cancer in the last 5 years.
Recent Findings: New targeted therapies are being identified for advanced and recurrent endometrial cancer. Within the last 5 years, pembrolizumab and lenvatinib have improved survival in advanced or recurrent endometrial cancer. Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer. Patients with recurrent endometrial cancer are often difficult to salvage. Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11912-021-01129-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endometriosis and cancer risk.
Eur J Cancer Prev
March 2025
Department of Oncology and Hemato-Oncology, University of Milan.
Endometriosis is one of the most common gynecological benign disease. Epidemiological evidence suggests a potential association between endometriosis and cancer risk. Accumulating evidence highlighted the risk of ovarian cancer, particularly endometrioid and clear cell subtypes.
View Article and Find Full Text PDFThe Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.
Cells
March 2025
SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP) Pan African Research Institute (PACRI), University of Pretoria, Hartfield, Pretoria 0028, South Africa.
The peremptory need to circumvent challenges associated with poorly differentiated epithelial endometrial cancers (PDEECs), also known as Type II endometrial cancers (ECs), has prompted therapeutic interrogation of the prototypically intractable and most prevalent gynecological malignancy. PDEECs account for most endometrial cancer-related mortalities due to their aggressive nature, late-stage detection, and poor response to standard therapies. PDEECs are characterized by heterogeneous histopathological features and distinct molecular profiles, and they pose significant clinical challenges due to their propensity for rapid progression.
View Article and Find Full Text PDFDevelopment of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.
Cells
February 2025
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Despite recent advances in cancer treatment, the prognosis for uterine malignancies (carcinoma and sarcoma) requires further improvement. Antibody-drug conjugates (ADCs) have emerged as a novel class of anti-cancer therapeutic agents, and multiple ADCs have been approved for other types of cancer. In 2024, trastuzumab deruxtecan received approval from the US Food and Drug Administration for cancer types and became the first ADC approved for the treatment of uterine malignancies.
View Article and Find Full Text PDFFeasibility of Measuring Context Specific Sedentary Behavior and Pulse Wave Velocity in Endometrial Cancer Survivors.
Integr Cancer Ther
March 2025
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Purpose: Sedentary behavior (SB) contributes to the heightened risk of cardiovascular disease (CVD) in endometrial cancer survivors (ECS). This feasibility study aimed to evaluate key outcomes to assess the practicality of SB reduction interventions for ECS. Secondary aims included SB domain assessment and preliminary efficacy testing of the relationship between SB and arterial stiffness.
View Article and Find Full Text PDFThe prognostic value of adipokine receptors leptinR and adiponectinR1 in obesity-inducible solid tumours.
Histol Histopathol
February 2025
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Background: With the rising incidence of life expectancy, obesity, and tumours, understanding the incretory influence of adipose tissue in tumorigenesis becomes increasingly important. As the adipokines leptin and adiponectin are released by fat tissue, we aimed to analyse the expression of their respective receptors in tumours for which an association with obesity is epidemiologically hypothesised.
Methods: The expression of leptinR and adipoR1 were analysed in cohorts of renal cell cancer (n=391), cervical cancer (n=155), vulvar cancer (n=107), and endometrial cancer (n=90) by immunohistochemistry and correlated with clinicopathological parameters including survival times.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!